Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 4Neoplasm Metastasis 3Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Ovarian Neoplasms 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Breast Neoplasms, Male 1

Interventions

Paclitaxel 69Bevacizumab 62Carboplatin 53pembrolizumab 46olaparib 32Specimen Handling 27Gemcitabine 27Cyclophosphamide 26Magnetic Resonance Spectroscopy 24liposomal doxorubicin 22Cisplatin 21niraparib 20Taxes 18Nivolumab 18fludarabine 17Topotecan 17Biopsy 17Doxorubicin 14Immunoglobulin G 12Fulvestrant 12Disulfides 12Oxaliplatin 10mirvetuximab soravtansine 9durvalumab 9aldesleukin 9Surveys and Questionnaires 9Ipilimumab 9Fluorouracil 9Blood Specimen Collection 9cemiplimab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Lapatinib × 1 year × Clear all
NCT04608409 2025-06-29

Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer

University of Kentucky

Phase 1 Completed
16 enrolled 14 charts
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡